Sander Brooks
YOU?
Author Swipe
View article: Pharmacological characterization of the selective orexin-1 receptor antagonist JNJ-61393215 in healthy volunteers
Pharmacological characterization of the selective orexin-1 receptor antagonist JNJ-61393215 in healthy volunteers Open
Background: Up to 40% of patients suffering from anxiety disorders do not benefit from currently available pharmacological treatments. Overactivity of the orexin-1 receptor (OX1R) has been implicated in anxiety- and panic-related states. A…
View article: Driving Performance after Bedtime Administration of Daridorexant, Assessed in a Sensitive Simulator
Driving Performance after Bedtime Administration of Daridorexant, Assessed in a Sensitive Simulator Open
Use of hypnotics is often associated with next‐morning residual effects and a higher risk of motor vehicle accidents. Measuring next‐morning effects on driving performance is therefore advised by regulatory agencies. Here, we examined driv…
View article: Phase 1 clinical trial of losmapimod in facioscapulohumeral dystrophy: Safety, tolerability, pharmacokinetics, and target engagement
Phase 1 clinical trial of losmapimod in facioscapulohumeral dystrophy: Safety, tolerability, pharmacokinetics, and target engagement Open
Aims Evaluate safety, tolerability, pharmacokinetics (PK) and target engagement (TE) of losmapimod in blood and muscle in facioscapulohumeral dystrophy (FSHD). Methods This study included Part A: 10 healthy volunteers randomized to single …
View article: 341 Acute effects of seltorexant, a selective orexin-2 antagonist (JNJ- 42847922), on driving after bedtime administration
341 Acute effects of seltorexant, a selective orexin-2 antagonist (JNJ- 42847922), on driving after bedtime administration Open
Introduction Seltorexant (JNJ-42847922), a potent and selective antagonist of the human orexin-2 receptor, is being developed for the treatment of major depressive disorder. Seltorexant also has sleep-promoting properties. Investigating th…
View article: 0377 Clinical Pharmacology Of The Dual Orexin Receptor Antagonist Act-541468 In Elderly Subjects
0377 Clinical Pharmacology Of The Dual Orexin Receptor Antagonist Act-541468 In Elderly Subjects Open
IntroductionThe orexin system regulates sleep and arousal. Following single-ascending dose (SAD) morning and repeated evening administration of ACT-541468, pharmacokinetics (PK), pharmacodynamics (PD), safety, tolerability, and residual ne…
View article: 0008 Night-Time Administration Of ACT-541468, A Novel Dual Orexin Receptor Antagonist: Characterization Of Its Pharmacokinetics, Next-Day Residual Effects, Safety, And Tolerability
0008 Night-Time Administration Of ACT-541468, A Novel Dual Orexin Receptor Antagonist: Characterization Of Its Pharmacokinetics, Next-Day Residual Effects, Safety, And Tolerability Open
IntroductionACT-541468 is a potent dual orexin receptor antagonist. The orexin system regulates sleep and arousal and is targeted by ACT-541468. Night-time pharmacokinetics (PK), next-day residual effects, safety, and tolerability followin…
View article: 0007 Multiple-Ascending-Dose Study Of ACT-541468, A Novel Dual Orexin Receptor Antagonist: Characterization Of Its Multiple-Dose Pharmacokinetics, Pharmacodynamics, Safety, And Tolerability
0007 Multiple-Ascending-Dose Study Of ACT-541468, A Novel Dual Orexin Receptor Antagonist: Characterization Of Its Multiple-Dose Pharmacokinetics, Pharmacodynamics, Safety, And Tolerability Open
IntroductionThe orexin system regulates sleep and arousal. Following entry-into-humans with ACT-541468, a dual orexin receptor antagonist, multiple-ascending oral dose pharmacokinetics (PK) including dose-proportionality and accumulation, …
View article: Light Fractionation Significantly Increases the Efficacy of Photodynamic Therapy Using BF-200 ALA in Normal Mouse Skin
Light Fractionation Significantly Increases the Efficacy of Photodynamic Therapy Using BF-200 ALA in Normal Mouse Skin Open
The present study illustrates the clinical potential of light fractionated PDT using BF-200 ALA for enhancing PDT efficacy in (pre-) malignant skin conditions such as basal cell carcinoma and vulval intraepithelial neoplasia and its applic…
View article: Sources of variability in the quantification of tissue optical properties by multidiameter single-fiber reflectance and fluorescence spectroscopy
Sources of variability in the quantification of tissue optical properties by multidiameter single-fiber reflectance and fluorescence spectroscopy Open
Recently, a multidiameter single-fiber reflectance and fluorescence spectroscopy device has been developed that enabled us to extract the autofluorescence of tissue that is corrected for the optical properties. Such a system has been incor…